“We delivered strong third quarter 2025 results, raised our full year guidance and are on track to deliver another year of double-digit top-line growth,” said Pablo Legorreta, Royalty Pharma’s (RPRX) founder and Chief Executive Officer. “In addition, we had an especially active past few months for deals, expanding our portfolio with three innovative therapies and increasing our Capital Deployment to $2.0 billion for the year. Furthermore, we hosted our Investor Day in September, where we highlighted the rapid growth in the royalty market, the powerful competitive advantages that underscore our leadership, our sustainable and attractive returns and our goal to be the premier capital allocator in life sciences with consistent, compounding growth.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M
- Royalty Pharma price target lowered to $54 from $55 at Morgan Stanley
- Royalty Pharma: Strategic Positioning and Growth Potential Drive Buy Rating
- Royalty Pharma initiated with a Buy at Goldman Sachs
- Royalty Pharma appoints Ted Love as lead independent director